Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ocular Therapeutix, Inc. (OCUL)
USD9.84
+0.14 (+1.39%)
US NASDAQ Healthcare Biotechnology
Address
24 Crosby Drive 1730
Bedford, MA, US
Bedford, MA, US
CEO
Pravin U. Dugel
Website
ocutx.com
IPO
2014-07-25
CIK 1393434 ISIN US67576A1007
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.84
+0.14 (+1.39%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.90
Float Shares
196.84M
Free Float %
90.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.29% | -4.78% | +3.39% | +3.15% | -18.14% | -24.55% | +30.86% | +44.71% | -38.81% | -8.76% | -30.34% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
9.84
Low
21.00
+113.5%
Consensus
25.50
+159.3%
Median
25.50
+159.3%
High
30.00
+205.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 6 |
25.67
+161.0%
|
| All Time | 12 |
21.08
+114.3%
|
Quality scores
Altman Z-Score
5.56
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-18.7% Q1'26: +0.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-16.4% Q1'26: -5.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-498.3% Q1'26: -655.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-490.3% Q1'26: -865.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +6,593.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+18.3% Q1'26: +32.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.32× Q1'26: -0.22× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 6 EPS Ana. |
Dec 2027 9 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.75M
est: 1.97M (-11.2%)
|
1.89M
est: 2.42M (-22.1%)
|
1.92M
est: 1.98M (-2.8%)
|
1.99M
est: 1.97M (+0.8%)
|
4.23M
est: 4.55M (-7.1%)
|
17.40M
est: 22.33M (-22.1%)
|
43.52M
est: 45.03M (-3.3%)
|
51.49M
est: 50.82M (+1.3%)
|
58.44M
est: 61.10M (-4.3%)
|
63.72M
est: 63.74M (0.0%)
|
51.82M
est: 54.77M (-5.4%)
|
51.89M
47.06M – 56.63M
-5.2% YoY
|
110.89M
75.11M – 239.18M
+113.7% YoY
|
250.78M
248.61M – 252.96M
+126.1% YoY
|
584.66M
394.97M – 1.10B
+133.1% YoY
|
1.02B
690.11M – 1.91B
+74.7% YoY
|
| EBITDA |
-37.27M
est: -1.55M (-2,298.2%)
|
-42.14M
est: -1.91M (-2,107.2%)
|
-59.87M
est: -1.56M (-3,738.0%)
|
-55.95M
est: -1.56M (-3,494.5%)
|
-77.74M
est: -3.59M (-2,068.1%)
|
-146.10M
est: -17.61M (-729.8%)
|
2.54M
est: -8.55M (+129.7%)
|
-61.91M
est: -45.44M (-36.2%)
|
-66.42M
est: -48.16M (-37.9%)
|
-176.14M
est: -50.25M (-250.6%)
|
-249.78M
est: -43.17M (-478.5%)
|
-40.91M
-44.64M – -37.10M
+5.2% YoY
|
-87.42M
-188.55M – -59.21M
-113.7% YoY
|
-197.70M
-199.41M – -195.99M
-126.1% YoY
|
-460.90M
-863.30M – -311.37M
-133.1% YoY
|
-805.30M
-1.51B – -544.03M
-74.7% YoY
|
| EBIT |
-38.02M
est: -1.58M (-2,312.7%)
|
-43.02M
est: -1.94M (-2,121.9%)
|
-61.49M
est: -1.58M (-3,787.4%)
|
-58.24M
est: -1.58M (-3,589.3%)
|
-80.27M
est: -3.64M (-2,107.5%)
|
-148.87M
est: -17.86M (-733.8%)
|
118.0K
est: -121.19M (+100.1%)
|
-64.02M
est: -115.63M (+44.6%)
|
-69.40M
est: -48.84M (-42.1%)
|
-179.93M
est: -50.96M (-253.1%)
|
-254.10M
est: -43.78M (-480.4%)
|
-41.49M
-45.27M – -37.62M
+5.2% YoY
|
-88.66M
-191.21M – -60.05M
-113.7% YoY
|
-200.49M
-202.23M – -198.75M
-126.1% YoY
|
-467.41M
-875.48M – -315.76M
-133.1% YoY
|
-816.67M
-1.53B – -551.71M
-74.7% YoY
|
| Net Income |
-39.75M
est: -267.99M (+85.2%)
|
-44.70M
est: -271.95M (+83.6%)
|
-63.39M
est: -361.11M (+82.4%)
|
-57.69M
est: -245.05M (+76.5%)
|
-86.37M
est: -280.76M (+69.2%)
|
-155.64M
est: -186.98M (+16.8%)
|
-6.55M
est: -1.33M (-394.1%)
|
-71.04M
est: -90.73M (+21.7%)
|
-80.74M
est: -138.36M (+41.6%)
|
-193.51M
est: -220.99M (+12.4%)
|
-265.94M
est: -268.26M (+0.9%)
|
-266.12M
-325.47M – -206.77M
+0.8% YoY
|
-332.57M
-357.06M – -141.59M
-25.0% YoY
|
-202.75M
-345.47M – -107.55M
+39.0% YoY
|
-43.07M
-91.94M – -24.90M
+78.8% YoY
|
234.36M
135.52M – 500.36M
+644.2% YoY
|
| SGA |
13.02M
est: 3.42M (+281.1%)
|
17.71M
est: 4.20M (+321.9%)
|
32.51M
est: 3.43M (+848.1%)
|
23.73M
est: 3.42M (+593.5%)
|
46.61M
est: 7.88M (+491.4%)
|
49.47M
est: 38.70M (+27.8%)
|
67.07M
est: 78.03M (-14.0%)
|
72.15M
est: 88.05M (-18.1%)
|
74.49M
est: 99.02M (-24.8%)
|
102.24M
est: 103.30M (-1.0%)
|
118.30M
est: 88.77M (+33.3%)
|
84.11M
76.28M – 91.78M
-5.2% YoY
|
179.74M
121.73M – 387.66M
+113.7% YoY
|
406.46M
402.94M – 409.99M
+126.1% YoY
|
947.60M
640.16M – 1.77B
+133.1% YoY
|
1.66B
1.12B – 3.10B
+74.7% YoY
|
| EPS |
-1.71
est: -1.69 (-1.0%)
|
-1.80
est: -1.72 (-4.8%)
|
-2.20
est: -2.28 (+3.6%)
|
-1.57
est: -1.55 (-1.4%)
|
-1.91
est: -1.77 (-7.7%)
|
-2.56
est: -1.18 (-116.7%)
|
-1.05
est: -1.03 (-1.9%)
|
-1.04
est: -0.95 (-9.8%)
|
-1.09
est: -1.20 (+9.1%)
|
-1.22
est: -1.18 (-3.4%)
|
-1.42
est: -1.45 (+2.3%)
|
-1.55
-1.74 – -1.10
-7.0% YoY
|
-1.45
-1.91 – -0.76
+6.9% YoY
|
-1.23
-1.85 – -0.57
+15.2% YoY
|
-0.23
-0.49 – -0.13
+81.3% YoY
|
1.25
0.72 – 2.67
+644.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-05-05 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-244.04M
OE per share TTM
-1.22
Owner's Yield
-11.89%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
63
Total invested
159.99M
Insider transactions (90d)
0
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors LLC | 12.71M | 7.90% | 12.71M | — | 12.71M | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 2 | Behzad Aghazadeh | 12.71M | 7.90% | 12.71M | — | 12.71M | — | IN | United States | 2024-11-14 | ↗ |
| 3 | (1) BlackRock, Inc. | 11.35M | 7.30% | — | — | 11.35M | — | HC | Delaware | 2024-10-22 | ↗ |
| 4 | David Kroin | 9.23M | 8.38% | — | 9.23M | — | — | HC, IN | Cayman Islands | 2023-12-22 | ↗ |
| 5 | Deep Track Biotechnology Master Fund, Ltd. | 9.23M | 8.38% | — | 9.23M | — | — | CO | Cayman Islands | 2023-12-22 | ↗ |
| 6 | Deep Track Capital, LP | 9.23M | 8.38% | — | 9.23M | — | — | IA, OO | Cayman Islands | 2023-12-22 | ↗ |
| 7 | Koh, Bong | 7.78M | 6.80% | — | 7.78M | — | — | IN | United States | 2023-12-28 | ↗ |
| 8 | Shah, Nimish | 7.78M | 6.80% | — | 7.78M | — | — | IN | United States | 2023-12-28 | ↗ |
| 9 | VHCP Co-Investment Holdings III, LLC | 7.78M | 6.80% | — | 7.78M | — | — | OO | Delaware | 2023-12-28 | ↗ |
| 10 | VHCP Management EG, LLC | 7.78M | 6.80% | — | 7.78M | — | — | OO | Delaware | 2023-12-28 | ↗ |
| 11 | VHCP Management III, LLC | 7.78M | 6.80% | — | 7.78M | — | — | OO | Delaware | 2023-12-28 | ↗ |
| 12 | Venrock Healthcare Capital Partners EG, L.P. | 7.78M | 6.80% | — | 7.78M | — | — | PN | Delaware | 2023-12-28 | ↗ |
| 13 | Venrock Healthcare Capital Partners III, L.P. | 7.78M | 6.80% | — | 7.78M | — | — | PN | Delaware | 2023-12-28 | ↗ |
| 14 | Opaleye Management Inc. | 5.97M | 7.80% | — | 5.97M | — | 5.97M | CO | Massachusetts | 2022-02-01 | ↗ |
| 15 | The Vanguard Group - 23-1945930 | 4.08M | 5.32% | — | — | 3.88M | 197.1K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 16 | Summer Road LLC * | 3.03M | 8.40% | 3.03M | — | 3.03M | — | OO | Delaware | 2018-02-07 | ↗ |
| 17 | 13 G | 2.96M | 11.00% | — | 2.96M | — | 2.96M | IN | United States of America | 2015-02-17 | ↗ |
| 18 | Capital Research Global Investors ** | 2.84M | 11.50% | 2.84M | — | 2.84M | — | IA | Delaware | 2015-07-10 | ↗ |
| 19 | GLG PARTNERS LP | 2.46M | 5.74% | — | 2.46M | — | 2.46M | PN | United Kingdom | 2019-05-31 | ↗ |
| 20 | MAN GROUP PLC | 2.46M | 5.74% | — | 2.46M | — | 2.46M | HC, OO | United Kingdom | 2019-05-31 | ↗ |
| 21 | Abigail P. Johnson | 2.10M | 5.11% | — | — | 2.10M | — | IN | United States of America | 2018-12-10 | ↗ |
| 22 | FMR LLC | 2.10M | 5.11% | — | — | 2.10M | — | HC | Delaware | 2018-12-10 | ↗ |
| 23 | Identification #52-2069785 (formerly 13-2631108) | 1.99M | 11.00% | 1.99M | — | — | 1.99M | IA | Delaware | 2017-07-10 | ↗ |
| 24 | Page | 1.93M | 7.80% | 1.93M | — | 1.93M | — | PN | DELAWARE | 2016-02-16 | ↗ |
| 25 | of 10 | 1.93M | 7.80% | — | — | 1.93M | — | PN | DELAWARE | 2016-02-16 | ↗ |
| 26 | Federated Investors, Inc. | 1.65M | 6.66% | 1.65M | — | 1.65M | — | HC | Citizenship or place of Organization | 2016-02-11 | ↗ |
| 27 | J. Christopher Donahue | 1.65M | 6.66% | — | 1.65M | — | 1.65M | IN | Citizenship or place of Organization | 2016-02-11 | ↗ |
| 28 | John F. Donahue | 1.65M | 6.66% | — | 1.65M | — | 1.65M | IN | Citizenship or place of Organization | 2016-02-11 | ↗ |
| 29 | Rhodora J. Donahue | 1.65M | 6.66% | — | 1.65M | — | 1.65M | IN | Citizenship or place of Organization | 2016-02-11 | ↗ |
| 30 | Voting Shares Irrevocable Trust | 1.65M | 6.66% | 1.65M | — | 1.65M | — | OO | Citizenship or place of Organization | 2016-02-11 | ↗ |
| 31 | Wellington Group Holdings LLP | 930.6K | 3.76% | — | 793.2K | — | — | HC | Massachusetts | 2016-02-11 | ↗ |
| 32 | Wellington Investment Advisors Holdings LLP | 930.6K | 3.76% | — | 793.2K | — | — | HC | Massachusetts | 2016-02-11 | ↗ |
| 33 | Wellington Management Group LLP | 930.6K | 3.76% | — | 793.2K | — | — | HC | Massachusetts | 2016-02-11 | ↗ |
| 34 | 1 | 9.00 | 11.00% | — | 2.20M | — | 2.20M | PN | Massachusetts | 2019-05-03 | ↗ |
| 35 | of 6 Pages | — | 0.00% | — | — | — | — | PN | Missouri | 2016-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
63
-201 vs prev Q
New positions
18
Closed positions
206
Increased
39
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 784.0K +784.0K (+100.0%) | 9.52B +9.5B (+100.0%) | 0.42% +0.419 pp | 3.14% +3.145 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 31.79M -29.0 (0.0%) | 385.88M +14.3M (+3.8%) | 16.98% -1.441 pp | 0.02% +0.000 pp | USD10.16 +19.5% | 45 qtrs — |
| 3 | BLACKROCK, INC. | 15.60M +5.0M (+47.8%) | 189.41M +66.0M (+53.5%) | 8.33% +2.216 pp | 0.00% +0.001 pp | USD9.80 +23.9% | 6 qtrs — |
| 4 | VANGUARD GROUP INC | 11.58M +2.4M (+26.3%) | 140.52M +33.4M (+31.2%) | 6.18% +0.873 pp | 0.00% +0.000 pp | USD9.54 +27.3% | 46 qtrs — |
| 5 | SUMMER ROAD LLC | 11.11M -1.5M (-11.7%) | 134.86M -12.2M (-8.3%) | 5.93% -1.356 pp | 97.92% -0.648 pp | USD7.00 +73.4% | 32 qtrs — |
| 6 | AVORO CAPITAL ADVISORS LLC | 10.78M +527.8K (+5.1%) | 130.84M +11.0M (+9.2%) | 5.76% -0.183 pp | 1.26% -0.291 pp | USD9.49 +27.9% | 8 qtrs — |
| 7 | DEEP TRACK CAPITAL, LP | 8.07M -3.9M (-32.4%) | 97.97M -41.5M (-29.8%) | 4.31% -2.603 pp | 1.75% -2.146 pp | USD5.82 +108.6% | 9 qtrs — |
| 8 | VR ADVISER, LLC | 7.32M -5.8M (-44.4%) | 88.81M -65.0M (-42.3%) | 3.91% -3.719 pp | 4.39% -4.273 pp | USD6.28 +93.3% | 9 qtrs — |
| 9 | TCG CROSSOVER MANAGEMENT, LLC | 5.74M -377.0K (-6.2%) | 69.69M -1.8M (-2.6%) | 3.07% -0.479 pp | 2.31% -1.212 pp | USD9.08 +33.7% | 8 qtrs — |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.63M +620.7K (+15.5%) | 56.15M +9.3M (+19.9%) | 2.47% +0.150 pp | 0.09% +0.011 pp | USD7.83 +55.0% | 8 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 4.36M +1.0M (+30.5%) | 52.90M +13.9M (+35.5%) | 2.33% +0.392 pp | 0.00% +0.001 pp | USD9.24 +31.4% | 46 qtrs — |
| 12 | ALLIANCEBERNSTEIN L.P. | 4.34M +917.5K (+26.8%) | 52.71M +12.7M (+31.7%) | 2.32% +0.335 pp | 0.02% +0.004 pp | USD11.60 +4.7% | 44 qtrs — |
| 13 | JANUS HENDERSON GROUP PLC | 4.23M +2.2M (+106.5%) | 51.32M +27.4M (+114.2%) | 2.26% +1.072 pp | 0.02% +0.012 pp | USD11.86 +2.4% | 7 qtrs — |
| 14 | STATE STREET CORP | 4.20M +736.3K (+21.3%) | 50.94M +10.5M (+25.9%) | 2.24% +0.236 pp | 0.00% +0.000 pp | USD9.07 +33.8% | 46 qtrs — |
| 15 | LOGOS GLOBAL MANAGEMENT LP | 3.50M +250.0K (+7.7%) | 42.49M +4.5M (+11.8%) | 1.87% -0.014 pp | 2.57% -0.838 pp | USD8.01 +51.6% | 9 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 3.21M -647.8K (-16.8%) | 38.94M -6.1M (-13.6%) | 1.71% -0.521 pp | 0.02% -0.003 pp | USD11.62 +4.5% | 5 qtrs — |
| 17 | PARADIGM BIOCAPITAL ADVISORS LP | 2.94M -562.0K (-16.1%) | 35.63M -5.2M (-12.8%) | 1.57% -0.459 pp | 0.91% -0.253 pp | USD8.60 +41.2% | 4 qtrs — |
| 18 | OCTAGON CAPITAL ADVISORS LP | 2.62M -400.0 (0.0%) | 31.85M +1.2M (+3.8%) | 1.40% -0.119 pp | 3.87% -0.783 pp | USD8.92 +36.1% | 8 qtrs — |
| 19 | DELTEC ASSET MANAGEMENT LLC | 2.49M -274.5K (-9.9%) | 30.20M -2.1M (-6.5%) | 1.35% -0.248 pp | 5.00% -0.322 pp | USD5.59 +117.2% | 37 qtrs — |
| 20 | CITADEL ADVISORS LLC | 2.48M -3.2M (-56.6%) | 30.06M -36.6M (-54.9%) | 1.32% -1.983 pp | 0.00% -0.006 pp | USD7.27 +67.0% | 33 qtrs — |
| 21 | WOODLINE PARTNERS LP | 1.67M +49.0 (+0.0%) | 20.23M +750.3K (+3.9%) | 0.89% -0.076 pp | 0.08% -0.013 pp | USD10.34 +17.4% | 6 qtrs — |
| 22 | OPALEYE MANAGEMENT INC. | 1.60M +— (+0.0%) | 19.36M +717.8K (+3.8%) | 0.85% -0.072 pp | 2.55% -0.082 pp | USD5.86 +107.2% | 31 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 1.55M +751.6K (+94.4%) | 18.79M +9.5M (+101.9%) | 0.83% +0.365 pp | 0.00% +0.001 pp | USD10.38 +17.0% | 39 qtrs — |
| 24 | SATURN V CAPITAL MANAGEMENT LLC | 1.50M +353.2K (+30.7%) | 18.27M +4.8M (+35.7%) | 0.80% +0.136 pp | 3.35% +0.400 pp | USD10.01 +21.3% | 5 qtrs — |
| 25 | NORTHERN TRUST CORP | 1.46M +287.2K (+24.4%) | 17.75M +4.0M (+29.2%) | 0.78% +0.100 pp | 0.00% +0.001 pp | USD9.88 +22.9% | 46 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.46M +336.4K (+29.9%) | 17.73M +4.6M (+34.9%) | 0.78% +0.129 pp | 0.00% +0.001 pp | USD9.78 +24.1% | 44 qtrs — |
| 27 | MARSHALL WACE, LLP | 1.38M -224.2K (-14.0%) | 16.72M -2.0M (-10.7%) | 0.74% -0.192 pp | 0.02% -0.004 pp | USD11.69 +3.8% | 2 qtrs — |
| 28 | UBS GROUP AG | 1.24M -3.3K (-0.3%) | 15.11M +521.4K (+3.6%) | 0.66% -0.058 pp | 0.00% +0.000 pp | USD8.14 +49.1% | 45 qtrs — |
| 29 | D. E. SHAW & CO., INC. | 1.15M +1.0M (+918.6%) | 14.01M +12.7M (+957.9%) | 0.62% +0.551 pp | 0.01% +0.007 pp | USD11.81 +2.8% | 5 qtrs — |
| 30 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 1.06M -13.0K (-1.2%) | 12.91M +326.4K (+2.6%) | 0.57% -0.056 pp | 0.02% +0.002 pp | USD8.70 +39.5% | 6 qtrs — |
| 31 | ACUTA CAPITAL PARTNERS, LLC | 1.05M -112.2K (-9.6%) | 12.78M -837.9K (-6.2%) | 0.56% -0.113 pp | 8.68% -5.397 pp | USD7.31 +66.1% | 9 qtrs — |
| 32 | JANE STREET GROUP, LLC | 1.03M +680.4K (+192.3%) | 12.56M +8.4M (+203.6%) | 0.55% +0.347 pp | 0.00% +0.001 pp | USD11.53 +5.3% | 24 qtrs — |
| 33 | POINT72 ASSET MANAGEMENT, L.P. | 1.02M -3.6M (-77.9%) | 12.34M -41.5M (-77.1%) | 0.54% -2.123 pp | 0.01% -0.076 pp | USD9.85 +23.2% | 7 qtrs — |
| 34 | INVESCO LTD. | 895.7K -148.2K (-14.2%) | 10.87M -1.3M (-10.9%) | 0.48% -0.127 pp | 0.00% 0.000 pp | USD8.94 +35.8% | 24 qtrs — |
| 35 | MORGAN STANLEY | 879.1K -1.6M (-64.3%) | 10.67M -18.2M (-63.0%) | 0.47% -0.959 pp | 0.00% -0.001 pp | USD8.20 +48.0% | 46 qtrs — |
| 36 | BARCLAYS PLC | 857.6K +346.1K (+67.7%) | 10.41M +6.0M (+134.0%) | 0.46% +0.162 pp | 0.00% +0.001 pp | USD9.48 +28.1% | 45 qtrs — |
| 37 | RAYMOND JAMES FINANCIAL INC | 842.2K -169.8K (-16.8%) | 10.22M -1.6M (-13.6%) | 0.45% -0.137 pp | 0.00% -0.001 pp | USD9.12 +33.1% | 5 qtrs — |
| 38 | CANDRIAM S.C.A. | 841.6K +841.6K (+100.0%) | 10.22M +10.2M (+100.0%) | 0.45% +0.450 pp | 0.05% +0.051 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 39 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 812.1K +812.1K (+100.0%) | 9.86M +9.9M (+100.0%) | 0.43% +0.434 pp | 0.03% +0.035 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 805.4K +627.4K (+352.5%) | 9.78M +7.7M (+369.9%) | 0.43% +0.327 pp | 0.00% +0.001 pp | USD11.95 +1.6% | 42 qtrs — |
| 41 | RENAISSANCE TECHNOLOGIES LLC | 791.2K +791.2K (+100.0%) | 9.61M +9.6M (+100.0%) | 0.42% +0.423 pp | 0.01% +0.015 pp | USD12.14 +0.0% | 4 qtrs — |
| 42 | QUBE RESEARCH & TECHNOLOGIES LTD | 769.8K +738.9K (+2,395.1%) | 9.35M +9.0M (+2,491.1%) | 0.41% +0.393 pp | 0.01% +0.009 pp | USD12.12 +0.2% | 2 qtrs — |
| 43 | BALYASNY ASSET MANAGEMENT L.P. | 763.6K -1.4M (-65.1%) | 9.27M -16.3M (-63.8%) | 0.41% -0.861 pp | 0.01% -0.021 pp | USD11.42 +6.3% | 5 qtrs — |
| 44 | CETERA INVESTMENT ADVISERS | 722.5K +8.5K (+1.2%) | 8.77M +424.2K (+5.1%) | 0.39% -0.028 pp | 0.01% 0.000 pp | USD8.34 +45.6% | 18 qtrs — |
| 45 | CATALIO CAPITAL MANAGEMENT, LP | 714.5K +714.5K (+100.0%) | 8.67M +8.7M (+100.0%) | 0.38% +0.382 pp | 1.53% +1.533 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 46 | ASSENAGON ASSET MANAGEMENT S.A. | 620.8K +575.2K (+1,261.4%) | 7.54M +7.0M (+1,313.8%) | 0.34% +0.311 pp | 0.01% +0.010 pp | USD11.79 +3.0% | 6 qtrs — |
| 47 | CAPTION MANAGEMENT, LLC | 615.1K +565.1K (+1,130.2%) | 7.47M +6.9M (+1,177.6%) | 0.33% +0.300 pp | 0.05% +0.047 pp | USD11.91 +1.9% | 3 qtrs — |
| 48 | CITIGROUP INC | 601.9K -71.4K (-10.6%) | 7.31M -564.2K (-7.2%) | 0.32% -0.069 pp | 0.00% 0.000 pp | USD11.21 +8.3% | 36 qtrs — |
| 49 | BANK OF AMERICA CORP /DE/ | 601.4K +154.2K (+34.5%) | 7.30M +2.1M (+39.7%) | 0.32% +0.062 pp | 0.00% +0.000 pp | USD8.38 +44.9% | 44 qtrs — |
| 50 | KNOLL CAPITAL MANAGEMENT, LLC | 600.4K +— (+0.0%) | 7.28M +258.2K (+3.7%) | 0.32% -0.027 pp | 3.34% -0.423 pp | USD7.29 +66.5% | 12 qtrs — |
| 51 | TREXQUANT INVESTMENT LP | 592.9K +405.1K (+215.7%) | 7.20M +5.0M (+227.9%) | 0.32% +0.208 pp | 0.06% +0.042 pp | USD12.00 +1.2% | 2 qtrs — |
| 52 | DEUTSCHE BANK AG\ | 590.7K +278.6K (+89.3%) | 7.17M +3.5M (+96.6%) | 0.32% +0.135 pp | 0.00% +0.001 pp | USD10.64 +14.1% | 46 qtrs — |
| 53 | PEREGRINE CAPITAL MANAGEMENT LLC | 571.1K -46.4K (-7.5%) | 6.93M -285.6K (-4.0%) | 0.31% -0.047 pp | 0.21% -0.005 pp | USD7.36 +64.9% | 4 qtrs — |
| 54 | JPMORGAN CHASE & CO | 550.3K +274.1K (+99.3%) | 6.68M +3.5M (+106.9%) | 0.29% +0.134 pp | 0.00% +0.000 pp | USD10.27 +18.2% | 36 qtrs — |
| 55 | DIADEMA PARTNERS LP | 545.2K +408.5K (+298.8%) | 6.62M +5.0M (+314.2%) | 0.29% +0.212 pp | 1.14% +0.731 pp | USD11.16 +8.8% | 5 qtrs — |
| 56 | EMPIRE LIFE INVESTMENTS INC. | 540.1K +288.9K (+115.0%) | 6.56M +3.6M (+123.2%) | 0.29% +0.148 pp | 0.37% +0.197 pp | USD11.93 +1.8% | 2 qtrs — |
| 57 | STEMPOINT CAPITAL LP | 522.7K +163.2K (+45.4%) | 6.35M +2.1M (+51.0%) | 0.28% +0.071 pp | 1.09% +0.246 pp | USD11.83 +2.6% | 4 qtrs — |
| 58 | APTUS CAPITAL ADVISORS, LLC | 500.8K +98.3K (+24.4%) | 6.08M +1.4M (+29.2%) | 0.27% +0.034 pp | 0.04% +0.009 pp | USD8.41 +44.4% | 7 qtrs — |
| 59 | SECOND LINE CAPITAL, LLC | 500.7K +98.3K (+24.4%) | 6.08M +1.4M (+29.2%) | 0.27% +0.034 pp | 1.25% +0.275 pp | USD8.41 +44.4% | 7 qtrs — |
| 60 | BANK OF NEW YORK MELLON CORP | 490.3K +89.5K (+22.3%) | 5.95M +1.3M (+27.0%) | 0.26% +0.030 pp | 0.00% +0.000 pp | USD10.09 +20.3% | 46 qtrs — |
| 61 | PATIENT SQUARE CAPITAL LP | 490.0K -225.0K (-31.5%) | 5.95M -2.4M (-28.8%) | 0.26% -0.153 pp | 1.27% -0.962 pp | USD7.99 +51.9% | 6 qtrs — |
| 62 | NUVEEN, LLC | 462.8K +117.4K (+34.0%) | 5.62M +1.6M (+39.2%) | 0.25% +0.047 pp | 0.00% +0.000 pp | USD8.55 +42.0% | 4 qtrs — |
| 63 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 445.4K +444.4K (+44,845.0%) | 5.41M +5.4M (+44,966.7%) | 0.24% +0.237 pp | 0.01% +0.006 pp | USD12.13 +0.1% | 3 qtrs — |
| 64 | SQUAREPOINT OPS LLC | 440.4K +89.7K (+25.6%) | 5.35M +1.2M (+30.4%) | 0.24% +0.032 pp | 0.01% +0.002 pp | USD11.78 +3.1% | 11 qtrs — |
| 65 | SUPERSTRING CAPITAL MANAGEMENT LP | 418.1K +418.1K (+100.0%) | 5.08M +5.1M (+100.0%) | 0.22% +0.223 pp | 2.72% +2.717 pp | USD12.14 +0.0% | 4 qtrs — |
| 66 | HRT FINANCIAL LP | 403.0K +80.0K (+24.8%) | 4.89M +1.1M (+29.6%) | 0.22% +0.028 pp | 0.02% +0.002 pp | USD11.78 +3.1% | 2 qtrs — |
| 67 | ROSALIND ADVISORS, INC. | 400.0K +— (+0.0%) | 4.86M +180.0K (+3.8%) | 0.21% -0.018 pp | 1.71% +0.108 pp | USD7.31 +66.1% | 7 qtrs — |
| 68 | AMERIPRISE FINANCIAL INC | 395.6K -159.6K (-28.7%) | 4.80M -1.7M (-26.0%) | 0.21% -0.110 pp | 0.00% 0.000 pp | USD10.45 +16.2% | 26 qtrs — |
| 69 | Y-INTERCEPT (HONG KONG) LTD | 395.3K +395.3K (+100.0%) | 4.80M +4.8M (+100.0%) | 0.21% +0.211 pp | 0.11% +0.107 pp | USD12.14 +0.0% | 3 qtrs — |
| 70 | ESSEX INVESTMENT MANAGEMENT CO LLC | 385.8K -8.3K (-2.1%) | 4.68M +77.2K (+1.7%) | 0.21% -0.022 pp | 0.71% +0.009 pp | USD5.07 +139.4% | 11 qtrs — |
| 71 | CENTIVA CAPITAL, LP | 381.9K +359.0K (+1,567.7%) | 4.64M +4.4M (+1,631.9%) | 0.20% +0.191 pp | 0.04% +0.035 pp | USD12.11 +0.2% | 2 qtrs — |
| 72 | TWO SIGMA INVESTMENTS, LP | 380.7K +146.5K (+62.5%) | 4.62M +1.9M (+68.8%) | 0.20% +0.068 pp | 0.01% +0.002 pp | USD10.53 +15.3% | 24 qtrs — |
| 73 | TUDOR INVESTMENT CORP ET AL | 379.8K +12.5K (+3.4%) | 4.61M +317.0K (+7.4%) | 0.20% -0.010 pp | 0.01% +0.001 pp | USD11.70 +3.8% | 2 qtrs — |
| 74 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 345.8K +45.8K (+15.3%) | 4.20M +691.3K (+19.7%) | 0.18% +0.011 pp | 0.22% +0.010 pp | USD11.75 +3.3% | 2 qtrs — |
| 75 | HIGHVISTA STRATEGIES LLC | 344.1K +237.5K (+222.7%) | 4.18M +2.9M (+235.2%) | 0.18% +0.122 pp | 1.08% +0.770 pp | USD10.86 +11.8% | 7 qtrs — |
| 76 | SWISS NATIONAL BANK | 313.3K +112.6K (+56.1%) | 3.80M +1.5M (+62.1%) | 0.17% +0.051 pp | 0.00% +0.001 pp | USD8.79 +38.1% | 7 qtrs — |
| 77 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 313.0K +313.0K (+100.0%) | 3.80M +3.8M (+100.0%) | 0.17% +0.167 pp | 0.35% +0.353 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 78 | UBS ASSET MANAGEMENT AMERICAS INC | 307.7K +106.5K (+52.9%) | 3.74M +1.4M (+58.8%) | 0.16% +0.048 pp | 0.00% +0.000 pp | USD9.38 +29.4% | 7 qtrs — |
| 79 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 305.8K +195.9K (+178.2%) | 3.71M +2.4M (+188.9%) | 0.16% +0.100 pp | 0.04% +0.035 pp | USD11.72 +3.6% | 5 qtrs — |
| 80 | JACOBS LEVY EQUITY MANAGEMENT, INC | 293.3K +293.3K (+100.0%) | 3.56M +3.6M (+100.0%) | 0.16% +0.157 pp | 0.01% +0.014 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 81 | FIRST TRUST ADVISORS LP | 268.7K -70.9K (-20.9%) | 3.26M -708.3K (-17.8%) | 0.14% -0.053 pp | 0.00% -0.001 pp | USD11.69 +3.8% | 5 qtrs — |
| 82 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 265.0K +63.0K (+31.2%) | 3.22M +855.7K (+36.2%) | 0.14% +0.025 pp | 0.30% +0.039 pp | USD11.80 +2.9% | 2 qtrs — |
| 83 | BNP PARIBAS ARBITRAGE, SNC | 255.9K +226.4K (+767.7%) | 3.11M +2.8M (+801.1%) | 0.14% +0.120 pp | 0.00% +0.001 pp | USD11.78 +3.1% | 44 qtrs — |
| 84 | WELLS FARGO & COMPANY/MN | 255.2K +124.4K (+95.0%) | 3.10M +1.6M (+102.6%) | 0.14% +0.061 pp | 0.00% +0.000 pp | USD10.96 +10.8% | 45 qtrs — |
| 85 | RHUMBLINE ADVISERS | 241.3K +21.3K (+9.7%) | 2.93M +357.7K (+13.9%) | 0.13% +0.001 pp | 0.00% +0.000 pp | USD8.24 +47.3% | 43 qtrs — |
| 86 | WALLEYE CAPITAL LLC | 230.5K +169.7K (+278.9%) | 2.80M +2.1M (+293.5%) | 0.12% +0.088 pp | 0.01% +0.006 pp | USD12.02 +1.0% | 2 qtrs — |
| 87 | AQR CAPITAL MANAGEMENT LLC | 180.7K +34.8K (+23.9%) | 2.19M +488.7K (+28.7%) | 0.10% +0.012 pp | 0.00% +0.000 pp | USD10.24 +18.6% | 23 qtrs — |
| 88 | JUMP FINANCIAL, LLC | 173.8K +111.6K (+179.3%) | 2.11M +1.4M (+190.1%) | 0.09% +0.057 pp | 0.03% +0.017 pp | USD11.98 +1.3% | 2 qtrs — |
| 89 | VERITION FUND MANAGEMENT LLC | 171.6K +5.6K (+3.4%) | 2.08M +142.4K (+7.3%) | 0.09% -0.005 pp | 0.01% +0.000 pp | USD8.82 +37.6% | 6 qtrs — |
| 90 | PRICE T ROWE ASSOCIATES INC /MD/ | 171.5K +40.0K (+30.4%) | 2.08M +545.0K (+35.4%) | 0.09% +0.015 pp | 0.00% +0.000 pp | USD8.95 +35.6% | 21 qtrs — |
| 91 | SEI INVESTMENTS CO | 169.7K +53.6K (+46.1%) | 2.06M +702.5K (+51.8%) | 0.09% +0.023 pp | 0.00% +0.001 pp | USD9.10 +33.4% | 6 qtrs — |
| 92 | ROUNDANGLE ADVISORS LLC | 168.9K -7.9K (-4.5%) | 2.05M -16.9K (-0.8%) | 0.09% -0.011 pp | 1.49% -0.108 pp | USD8.54 +42.2% | 5 qtrs — |
| 93 | BEACON INVESTMENT ADVISORS LLC | 165.6K +165.6K (+100.0%) | 2.01M +2.0M (+100.0%) | 0.09% +0.088 pp | 0.81% +0.806 pp | USD12.14 +0.0% | 1 qtrs NEW |
| 94 | STATE OF WISCONSIN INVESTMENT BOARD | 162.8K +37.6K (+30.0%) | 1.98M +513.0K (+35.1%) | 0.09% +0.014 pp | 0.00% +0.001 pp | USD8.30 +46.3% | 8 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 88 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Pharmaceuticals ETF PJP | 3.29% | 11.78M | 0.57% |
| 2 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.75% | 8.23M | 0.35% |
| 3 | Simplify Propel Opportunities ETF SURI | 1.07% | 826.7K | 2.82% |
| 4 | iShares U.S. Pharmaceuticals ETF IHE | 0.40% | 5.40M | 0.38% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.36% | 84.6K | 1.22% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.16% | 1.71M | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.16% | 114.4K | 0.35% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.15% | 711.0K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.15% | 114.7K | 0.19% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.11% | 16.06M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.82
Bullish
Ratio by volume
3.00
Bullish
Buys
20
Sells
11
Shares acquired
3.03M
Shares disposed
197.2K
Cash buys
1.00
Cash sales
11.00
Net activity
+2,835,878
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-09 | Dugel Pravin | Director / Officer | G-Gift | D | Common Stock | 394,696 | 0.00 | — | 2,618,326 | D | ↗ |
| 2026-02-23 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,759 | 8.28 | 14.6K | 330,653 | D | ↗ |
| 2026-02-23 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 2,810 | 8.28 | 23.3K | 269,108 | D | ↗ |
| 2026-02-23 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 3,057 | 8.28 | 25.3K | 323,368 | D | ↗ |
| 2026-02-23 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 20,056 | 8.28 | 166.1K | 3,013,022 | D | ↗ |
| 2026-02-20 | Waheed Nadia | Officer | S-Sale | D | Common Stock | 3,510 | 7.74 | 27.2K | 314,907 | D | ↗ |
| 2026-02-20 | LINDSTROM RICHARD L MD | Director | P-Purchase | A | Common Stock | 60,229 | 7.66 | 461.4K | 246,933 | D | ↗ |
| 2026-02-12 | Waheed Nadia | Officer | S-Sale | D | Common Stock | 7,863 | 9.04 | 71.1K | 318,417 | D | ↗ |
| 2026-02-12 | Notman Donald | Officer | S-Sale | D | Common Stock | 11,446 | 9.04 | 103.5K | 366,356 | D | ↗ |
| 2026-02-12 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 10,348 | 9.04 | 93.5K | 332,412 | D | ↗ |
| 2026-02-12 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 124,882 | 9.04 | 1.13M | 3,033,078 | D | ↗ |
| 2026-02-04 | Notman Donald | Officer | S-Sale | D | Common Stock | 6,035 | 8.54 | 51.5K | 377,802 | D | ↗ |
| 2026-02-02 | Notman Donald | Officer | S-Sale | D | Common Stock | 5,455 | 9.14 | 49.9K | 383,837 | D | ↗ |
| 2026-01-21 | Robinson David Wayne | Officer | A-Award | A | Stock Option (Right to Buy) | 416,000 | 11.42 | 4.75M | 416,000 | D | ↗ |
| 2026-01-20 | Robins Jason Shand | Officer | A-Award | A | Stock Option (Right to Buy) | 33,000 | 11.45 | 377.9K | 33,000 | D | ↗ |
| 2026-01-02 | Waheed Nadia | Officer | A-Award | A | Stock Option (Right to Buy) | 240,932 | 11.82 | 2.85M | 240,932 | D | ↗ |
| 2026-01-02 | Saroj Namrata | Officer | A-Award | A | Stock Option (Right to Buy) | 240,932 | 11.82 | 2.85M | 240,932 | D | ↗ |
| 2026-01-02 | Notman Donald | Officer | A-Award | A | Stock Option (Right to Buy) | 240,932 | 11.82 | 2.85M | 240,932 | D | ↗ |
| 2026-01-02 | Nayak Sanjay | Officer | A-Award | A | Common Stock | 64,900 | 0.00 | — | 342,760 | D | ↗ |
| 2026-01-02 | Meyers Steve Lawrence | Officer | A-Award | A | Stock Option (Right to Buy) | 197,650 | 11.82 | 2.34M | 197,650 | D | ↗ |
| 2026-01-02 | Kaiser Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 240,932 | 11.82 | 2.85M | 240,932 | D | ↗ |
| 2026-01-02 | Heier Jeffrey S. | Officer | A-Award | A | Stock Option (Right to Buy) | 240,932 | 11.82 | 2.85M | 240,932 | D | ↗ |
| 2026-01-02 | Anderman Todd | Officer | A-Award | A | Common Stock | 64,900 | 0.00 | — | 152,468 | D | ↗ |
| 2025-11-26 | Dugel Pravin | Director / Officer | G-Gift | D | Common Stock | 49,754 | 0.00 | — | 0 | I | ↗ |
| 2025-11-24 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,878 | 12.04 | 22.6K | 277,860 | D | ↗ |
| 2025-11-24 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 3,007 | 12.02 | 36.1K | 191,433 | D | ↗ |
| 2025-11-24 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 3,469 | 12.04 | 41.8K | 245,940 | D | ↗ |
| 2025-11-24 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 19,530 | 12.04 | 235.1K | 3,157,960 | D | ↗ |
| 2025-11-05 | Saroj Namrata | Officer | S-Sale | D | Common Stock | 25,865 | 10.74 | 277.8K | 174,135 | D | ↗ |
| 2025-10-08 | Anderman Todd | Officer | S-Sale | D | Common Stock | 11,132 | 12.34 | 137.4K | 87,568 | D | ↗ |
| 2025-10-02 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 9,653 | 11.03 | 106.5K | 194,440 | D | ↗ |
| 2025-10-02 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 10,502 | 11.04 | 115.9K | 249,409 | D | ↗ |
| 2025-09-09 | Dugel Pravin | Director / Officer | G-Gift | D | Common Stock | 49,754 | 0.00 | — | 3,177,490 | D | ↗ |
| 2025-09-02 | Notman Donald | Officer | S-Sale | D | Common Stock | 1,066 | 12.43 | 13.3K | 308,807 | D | ↗ |
| 2025-08-25 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,885 | 12.04 | 22.7K | 279,738 | D | ↗ |
| 2025-08-25 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 3,011 | 12.04 | 36.3K | 204,093 | D | ↗ |
| 2025-08-25 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 3,063 | 12.04 | 36.9K | 259,911 | D | ↗ |
| 2025-08-25 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 21,494 | 12.04 | 258.8K | 3,227,244 | D | ↗ |
| 2025-08-12 | Waheed Nadia | Officer | A-Award | A | Common Stock | 40,363 | 0.00 | — | 247,168 | D | ↗ |
| 2025-08-11 | Dugel Pravin | Director / Officer | G-Gift | A | Common Stock | 250,361 | 0.00 | — | 250,361 | I | ↗ |
| 2025-06-12 | Dugel Pravin | Director / Officer | G-Gift | D | Common Stock | 50,029 | 0.00 | — | 3,248,738 | D | ↗ |
| 2025-06-11 | Williams Leslie J. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 8.82 | 388.1K | 44,000 | D | ↗ |
| 2025-06-11 | Warden Charles M | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 86,464 | D | ↗ |
| 2025-06-11 | Saroj Namrata | Officer | — | — | Stock Option (Right to Buy) | 316,000 | 10.27 | 3.25M | 0 | D | ↗ |
| 2025-06-11 | RAINES MERILEE | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 8.82 | 388.1K | 44,000 | D | ↗ |
| 2025-06-11 | Meyers Steve Lawrence | Officer | — | — | Stock Option (Right to Buy) | 45,000 | 5.22 | 234.9K | 0 | D | ↗ |
| 2025-06-11 | LINDSTROM RICHARD L MD | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 143,145 | D | ↗ |
| 2025-06-11 | Hong Seung Suh | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 8.82 | 388.1K | 44,000 | D | ↗ |
| 2025-06-11 | Graves Adrienne L | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-06-11 | Dugel Pravin | Director / Officer | A-Award | A | Performance Stock Option (Right to Buy) | 2,750,000 | 7.44 | 20.46M | 2,750,000 | D | ↗ |
| 2025-06-02 | Waheed Nadia | Officer | S-Sale | D | Common Stock | 13,861 | 8.05 | 111.6K | 206,805 | D | ↗ |
| 2025-05-23 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,862 | 7.17 | 13.4K | 281,623 | D | ↗ |
| 2025-05-23 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 2,974 | 7.17 | 21.3K | 207,104 | D | ↗ |
| 2025-05-23 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 3,024 | 7.18 | 21.7K | 262,974 | D | ↗ |
| 2025-05-23 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 21,219 | 7.18 | 152.4K | 3,499,099 | D | ↗ |
| 2025-05-08 | LINDSTROM RICHARD L MD | Director | P-Purchase | A | Common Stock | 10,000 | 6.96 | 69.6K | 172,704 | D | ↗ |
| 2025-04-28 | Dugel Pravin | Director / Officer | G-Gift | D | Common Stock | 200,332 | 0.00 | — | 3,298,767 | D | ↗ |
| 2025-02-24 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,895 | 6.84 | 13.0K | 283,485 | D | ↗ |
| 2025-02-24 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 3,009 | 6.87 | 20.7K | 210,078 | D | ↗ |
| 2025-02-24 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 3,061 | 6.87 | 21.0K | 265,998 | D | ↗ |
| 2025-02-24 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 21,475 | 6.87 | 147.5K | 3,520,318 | D | ↗ |
| 2025-02-11 | Waheed Nadia | Officer | A-Award | A | Stock Option (Right to Buy) | 237,000 | 7.44 | 1.76M | 237,000 | D | ↗ |
| 2025-02-11 | Notman Donald | Officer | A-Award | A | Stock Option (Right to Buy) | 344,115 | 7.44 | 2.56M | 344,115 | D | ↗ |
| 2025-02-11 | Nayak Sanjay | Officer | A-Award | A | Common Stock | 111,000 | 0.00 | — | 285,380 | D | ↗ |
| 2025-02-11 | Dugel Pravin | Director / Officer | A-Award | A | Common Stock | 1,250,000 | 0.00 | — | 2,041,793 | D | ↗ |
| 2025-02-04 | Notman Donald | Officer | S-Sale | D | Common Stock | 11,119 | 7.81 | 86.8K | 193,444 | D | ↗ |
| 2025-01-31 | Notman Donald | Officer | S-Sale | D | Common Stock | 6,301 | 7.84 | 49.4K | 204,563 | D | ↗ |
| 2024-11-25 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,814 | 9.00 | 16.3K | 174,380 | D | ↗ |
| 2024-11-25 | Kaiser Peter | Officer | S-Sale | D | Common Stock | 2,897 | 9.01 | 26.1K | 213,087 | D | ↗ |
| 2024-11-25 | Heier Jeffrey S. | Officer | S-Sale | D | Common Stock | 2,948 | 9.01 | 26.6K | 269,059 | D | ↗ |
| 2024-11-25 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 20,680 | 9.01 | 186.3K | 791,793 | D | ↗ |
| 2024-10-07 | Anderman Todd | Officer | A-Award | A | Stock Option (Right to Buy) | 296,500 | 9.48 | 2.81M | 296,500 | D | ↗ |
| 2024-10-02 | Kaiser Peter | Officer | — | — | Stock Option (Right to Buy) | 366,666 | 9.70 | 3.56M | 0 | D | ↗ |
| 2024-10-02 | Heier Jeffrey S. | Officer | — | — | Stock Option (Right to Buy) | 366,666 | 9.70 | 3.56M | 0 | D | ↗ |
| 2024-08-29 | Notman Donald | Officer | A-Award | A | Common Stock | 11,034 | 0.00 | — | 208,988 | — | ↗ |
| 2024-08-23 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 1,832 | 9.02 | 16.5K | 176,194 | — | ↗ |
| 2024-08-23 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 20,880 | 9.02 | 188.3K | 812,473 | — | ↗ |
| 2024-07-24 | Williams Leslie J. | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 37,433 | — | ↗ |
| 2024-07-24 | Warden Charles M | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 7.91 | 284.8K | 36,000 | — | ↗ |
| 2024-07-24 | RAINES MERILEE | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 7.91 | 284.8K | 36,000 | — | ↗ |
| 2024-07-24 | LINDSTROM RICHARD L MD | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 7.91 | 284.8K | 36,000 | — | ↗ |
| 2024-07-24 | Hong Seung Suh | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 32,933 | — | ↗ |
| 2024-07-24 | Graves Adrienne L | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 7.91 | 284.8K | 36,000 | — | ↗ |
| 2024-06-01 | Waheed Nadia | Officer | A-Award | A | Stock Option (Right to Buy) | 425,000 | 5.70 | 2.42M | 425,000 | — | ↗ |
| 2024-05-23 | Nayak Sanjay | Officer | S-Sale | D | Common Stock | 2,274 | 5.84 | 13.3K | 178,026 | — | ↗ |
| 2024-05-23 | Dugel Pravin | Director / Officer | S-Sale | D | Common Stock | 21,626 | 5.79 | 125.2K | 833,353 | — | ↗ |
| 2024-02-27 | LINDSTROM RICHARD L MD | Director | M-Exempt | D | Stock Option (Right to Buy) | 11,363 | 8.80 | 100.0K | 0 | — | ↗ |
| 2024-02-26 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 930,851 | 7.52 | 7.00M | 8,591,401 | — | ↗ |
| 2024-02-22 | Nayak Sanjay | Officer | A-Award | A | Stock Option (Right to Buy) | 244,550 | 9.70 | 2.37M | 244,550 | — | ↗ |
| 2024-02-22 | Dugel Pravin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,282,469 | 9.70 | 12.44M | 1,282,469 | — | ↗ |
| 2024-02-21 | Nayak Sanjay | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2024-02-21 | Dugel Pravin | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-05 | White Christopher G | Officer | S-Sale | A | Common Stock | 5,910 | 4.86 | 28.7K | 123,689 | — | ↗ |
| 2024-02-05 | Strassburger Philip C. | Officer | S-Sale | A | Common Stock | 6,029 | 4.86 | 29.3K | 161,493 | — | ↗ |
| 2024-02-05 | Ozden Rabia Gurses | Officer | S-Sale | A | Common Stock | 6,346 | 4.86 | 30.8K | 153,054 | — | ↗ |
| 2024-02-05 | Notman Donald | Officer | S-Sale | A | Common Stock | 6,212 | 4.86 | 30.2K | 195,356 | — | ↗ |
| 2024-02-05 | Mattessich Antony C. | Director / Officer | S-Sale | A | Common Stock | 19,642 | 4.86 | 95.5K | 588,701 | — | ↗ |
| 2024-02-03 | White Christopher G | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 5.18 | 621.6K | 120,000 | — | ↗ |
| 2024-02-03 | Strassburger Philip C. | Officer | A-Award | A | Common Stock | 58,304 | 0.00 | — | 167,522 | — | ↗ |
| 2024-02-03 | Ozden Rabia Gurses | Officer | A-Award | A | Common Stock | 66,633 | 0.00 | — | 159,400 | — | ↗ |
| 2024-02-03 | Notman Donald | Officer | A-Award | A | Stock Option (Right to Buy) | 185,000 | 5.18 | 958.3K | 185,000 | — | ↗ |
| 2024-02-03 | Mattessich Antony C. | Director / Officer | A-Award | A | Common Stock | 180,400 | 0.00 | — | 608,343 | — | ↗ |
| 2024-01-31 | White Christopher G | Officer | S-Sale | D | Common Stock | 5,147 | 4.95 | 25.5K | 89,619 | — | ↗ |
| 2024-01-31 | Strassburger Philip C. | Officer | S-Sale | D | Common Stock | 6,831 | 4.95 | 33.8K | 109,218 | — | ↗ |
| 2024-01-31 | Ozden Rabia Gurses | Officer | S-Sale | D | Common Stock | 7,764 | 4.95 | 38.4K | 92,767 | — | ↗ |
| 2024-01-31 | Notman Donald | Officer | S-Sale | D | Common Stock | 6,433 | 4.95 | 31.8K | 139,932 | — | ↗ |
| 2024-01-31 | Mattessich Antony C. | Director / Officer | S-Sale | D | Common Stock | 18,338 | 4.95 | 90.8K | 427,943 | — | ↗ |
| 2023-12-14 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 1,538,461 | 3.25 | 5.00M | 7,660,550 | — | ↗ |
| 2023-08-30 | Mattessich Antony C. | Director / Officer | P-Purchase | A | Common Stock | 6,500 | 3.81 | 24.8K | 6,500 | — | ↗ |
| 2023-08-02 | Heier Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 17,350 | 4.30 | 74.6K | 17,350 | — | ↗ |
| 2023-07-10 | Graves Adrienne L | Director | A-Award | A | Stock Option (Right to Buy) | 72,000 | 5.04 | 362.9K | 72,000 | — | ↗ |
| 2023-07-07 | Ozden Rabia Gurses | Officer | S-Sale | D | Common Stock | 832 | 4.93 | 4.1K | 100,531 | — | ↗ |
| 2023-06-14 | Williams Leslie J. | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 25,433 | — | ↗ |
| 2023-06-14 | Warden Charles M | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 5.31 | 191.2K | 36,000 | — | ↗ |
| 2023-06-14 | RAINES MERILEE | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 20,933 | — | ↗ |
| 2023-06-14 | LINDSTROM RICHARD L MD | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 120,402 | — | ↗ |
| 2023-06-14 | Hong Seung Suh | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 20,933 | — | ↗ |
| 2023-06-14 | Heier Jeffrey S. | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 59,933 | — | ↗ |
| 2023-02-06 | White Christopher G | Officer | S-Sale | D | Common Stock | 5,829 | 4.24 | 24.7K | 94,766 | — | ↗ |
| 2023-02-06 | Strassburger Philip C. | Officer | S-Sale | D | Common Stock | 6,181 | 4.24 | 26.2K | 109,071 | — | ↗ |
| 2023-02-06 | Ozden Rabia Gurses | Officer | S-Sale | D | Common Stock | 6,416 | 4.24 | 27.2K | 101,363 | — | ↗ |
| 2023-02-06 | Notman Donald | Officer | S-Sale | D | Common Stock | 6,476 | 4.24 | 27.5K | 139,387 | — | ↗ |
| 2023-02-06 | Mattessich Antony C. | Director / Officer | S-Sale | D | Common Stock | 19,669 | 4.24 | 83.4K | 446,281 | — | ↗ |
| 2023-01-30 | White Christopher G | Officer | A-Award | A | Common Stock | 44,444 | 0.00 | — | 100,595 | — | ↗ |
| 2023-01-30 | Strassburger Philip C. | Officer | A-Award | A | Stock Option (Right to Buy) | 166,667 | 3.88 | 646.7K | 166,667 | — | ↗ |
| 2023-01-30 | Ozden Rabia Gurses | Officer | A-Award | A | Common Stock | 55,556 | 0.00 | — | 107,779 | — | ↗ |
| 2023-01-30 | Notman Donald | Officer | A-Award | A | Common Stock | 55,556 | 0.00 | — | 145,863 | — | ↗ |
| 2023-01-30 | Mattessich Antony C. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 536,900 | 3.88 | 2.08M | 536,900 | — | ↗ |
| 2022-11-07 | SUMMER ROAD LLC | Director | P-Purchase | A | Common Stock, $0.0001 par value per share | 7,328 | 3.50 | 25.6K | 6,122,089 | — | ↗ |
| 2022-10-17 | Heier Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-10-13 | White Christopher G | Officer | A-Award | A | Stock Option (Right to Buy) | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2022-10-11 | SUMMER ROAD LLC | Director | P-Purchase | A | Common Stock, $0.0001 par value per share | 10,000 | 3.90 | 39.0K | 6,114,761 | — | ↗ |
| 2022-10-10 | SUMMER ROAD LLC | Director | P-Purchase | A | Common Stock, $0.0001 par value per share | 10,000 | 4.00 | 40.0K | 6,104,761 | — | ↗ |
| 2022-09-29 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 18,800 | 4.04 | 76.0K | 6,094,761 | — | ↗ |
| 2022-09-28 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 1,200 | 4.10 | 4.9K | 6,075,961 | — | ↗ |
| 2022-09-27 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 130,000 | 4.68 | 608.3K | 6,074,761 | — | ↗ |
| 2022-07-01 | Ozden Rabia Gurses | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-16 | Williams Leslie J. | Director | A-Award | A | Stock Option (Right to Buy) | 26,800 | 3.43 | 91.9K | 26,800 | — | ↗ |
| 2022-06-16 | Warden Charles M | Director | A-Award | A | Stock Option (Right to Buy) | 26,800 | 0.00 | — | 26,800 | — | ↗ |
| 2022-06-16 | RAINES MERILEE | Director | A-Award | A | Common Stock | 8,933 | 0.00 | — | 8,933 | — | ↗ |
| 2022-06-16 | LINDSTROM RICHARD L MD | Director | A-Award | A | Stock Option (Right to Buy) | 26,800 | 3.43 | 91.9K | 26,800 | — | ↗ |
| 2022-06-16 | Hong Seung Suh | Director | A-Award | A | Common Stock | 8,933 | 0.00 | — | 8,933 | — | ↗ |
| 2022-06-16 | Heier Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 26,800 | 0.00 | — | 26,800 | — | ↗ |
| 2022-05-12 | LINDSTROM RICHARD L MD | Director | M-Exempt | A | Common Stock | 9,469 | 1.22 | 11.6K | 99,469 | — | ↗ |
| 2022-05-12 | Heier Jeffrey S. | Director | P-Purchase | A | Common Stock | 15,000 | 3.05 | 45.8K | 39,000 | — | ↗ |
| 2022-02-23 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 10,000 | 4.80 | 48.0K | 5,944,761 | — | ↗ |
| 2022-02-18 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 40,000 | 5.00 | 199.9K | 5,934,761 | — | ↗ |
| 2022-02-03 | White Christopher G | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 52,127 | — | ↗ |
| 2022-02-03 | Strassburger Philip C. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 5.27 | 790.5K | 150,000 | — | ↗ |
| 2022-02-03 | Notman Donald | Officer | A-Award | A | Common Stock | 55,556 | 0.00 | — | 81,632 | — | ↗ |
| 2022-02-03 | Mattessich Antony C. | Officer | A-Award | A | Stock Option (Right to Buy) | 560,200 | 5.27 | 2.95M | 560,200 | — | ↗ |
| 2022-02-03 | Goldstein Michael H. | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 5.27 | 1.00M | 190,000 | — | ↗ |
| 2022-01-28 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 4,023 | 5.20 | 20.9K | 5,894,761 | — | ↗ |
| 2022-01-27 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 1,477 | 5.20 | 7.7K | 5,890,738 | — | ↗ |
| 2022-01-24 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 44,400 | 5.31 | 235.9K | 5,889,261 | — | ↗ |
| 2022-01-21 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 12,152 | 5.56 | 67.5K | 5,844,861 | — | ↗ |
| 2022-01-20 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 17,948 | 5.70 | 102.4K | 5,832,709 | — | ↗ |
| 2022-01-18 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 6,807 | 6.00 | 40.8K | 5,814,761 | — | ↗ |
| 2022-01-14 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 33,193 | 6.03 | 200.1K | 5,807,954 | — | ↗ |
| 2022-01-13 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 10,000 | 6.20 | 62.0K | 5,774,761 | — | ↗ |
| 2021-12-15 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 15,000 | 6.22 | 93.2K | 5,764,761 | — | ↗ |
| 2021-12-14 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 29,490 | 6.41 | 189.2K | 5,749,761 | — | ↗ |
| 2021-12-13 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 10,510 | 6.50 | 68.3K | 5,720,271 | — | ↗ |
| 2021-12-10 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 30,000 | 6.65 | 199.5K | 5,709,761 | — | ↗ |
| 2021-12-08 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 5,300 | 6.75 | 35.8K | 5,679,761 | — | ↗ |
| 2021-12-06 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 55,600 | 6.13 | 340.8K | 5,674,461 | — | ↗ |
| 2021-10-01 | White Christopher G | Officer | — | D | Stock Option (right to buy) | 73,309 | 4.39 | 321.8K | 0 | — | ↗ |
| 2021-09-20 | RAINES MERILEE | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 10.02 | 360.7K | 36,000 | — | ↗ |
| 2021-08-20 | Mattessich Antony C. | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 9.89 | 49.5K | 102,900 | — | ↗ |
| 2021-06-18 | Williams Leslie J. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-06-18 | Warden Charles M | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-06-18 | PEACOCK BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-06-18 | LINDSTROM RICHARD L MD | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-06-18 | Hong Seung Suh | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-06-18 | Heier Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 13.51 | 243.2K | 18,000 | — | ↗ |
| 2021-05-20 | LINDSTROM RICHARD L MD | Director | S-Sale | D | Common Stock | 10,000 | 14.30 | 143.0K | 90,000 | — | ↗ |
| 2021-02-17 | Strassburger Philip C. | Officer | A-Award | A | Stock Option (Right to Buy) | 51,900 | 18.31 | 950.3K | 51,900 | — | ↗ |
| 2021-02-17 | Notman Donald | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 18.31 | 3.48M | 190,000 | — | ↗ |
| 2021-02-17 | Mattessich Antony C. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 455,000 | 18.31 | 8.33M | 455,000 | — | ↗ |
| 2021-02-17 | Kitchen Patricia | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 18.31 | 4.03M | 220,000 | — | ↗ |
| 2021-02-17 | Goldstein Michael H. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 18.31 | 4.58M | 250,000 | — | ↗ |
| 2021-02-15 | Warden Charles M | Director | J-Other | A | Common Stock | 35,912 | 0.00 | — | 39,531 | — | ↗ |
| 2020-12-04 | Warden Charles M | Director | J-Other | D | Common Stock | 745,597 | 0.00 | — | 1,456,780 | — | ↗ |
| 2020-12-03 | PEACOCK BRUCE | Director | M-Exempt | A | Common Stock | 7,000 | 8.14 | 57.0K | 25,000 | — | ↗ |
| 2020-10-16 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 437 | 10.48 | 4.6K | 5,618,861 | — | ↗ |
| 2020-10-05 | Strassburger Philip C. | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 8.42 | 2.95M | 350,000 | — | ↗ |
| 2020-09-15 | Strassburger Philip C. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-25 | Williams Leslie J. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-06-25 | Warden Charles M | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-06-25 | PEACOCK BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-06-25 | LINDSTROM RICHARD L MD | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-06-25 | Hong Seung Suh | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-06-25 | Heier Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.75 | 157.5K | 18,000 | — | ↗ |
| 2020-05-19 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 363,636 | 5.50 | 2.00M | 5,618,424 | — | ↗ |
| 2020-04-03 | Opaleye Management Inc. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-24 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 35,052 | 4.87 | 170.7K | 5,254,788 | — | ↗ |
| 2020-03-23 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 64,948 | 4.66 | 302.4K | 5,219,736 | — | ↗ |
| 2020-03-20 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 9,100 | 4.52 | 41.1K | 5,154,788 | — | ↗ |
| 2020-03-19 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 40,900 | 4.63 | 189.2K | 5,145,688 | — | ↗ |
| 2020-03-18 | SUMMER ROAD LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 344,938 | 4.62 | 1.59M | 5,104,788 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.3K
Shares Outstanding
217.69M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Pravin U. Dugel, M.D. Executive Chair, President and Chief Executive Officer | 819.2K | 890.9K | 18.61M | 15.57M | — | 61.9K | 35.95M | 95.07% | ↗ |
| 2 | 2025 | Nadia Waheed, M.D. Chief Medical Officer | 536.7K | 398.8K | 1.09M | 2.35M | — | 378.00 | 4.38M | 78.63% | ↗ |
| 3 | 2025 | Donald Notman Chief Operating Officer and Chief Financial Officer | 560.2K | 406.1K | 855.6K | 1.85M | — | 2.9K | 3.67M | 73.60% | ↗ |
| 4 | 2025 | Sanjay Nayak, M.B.B.S., Ph.D. Chief Strategy Officer | 510.0K | 332.8K | 825.8K | 1.79M | — | 2.9K | 3.46M | 75.58% | ↗ |
| 5 | 2025 | Steve Meyers Chief Commercial Officer | 510.0K | 295.8K | 550.6K | 1.19M | — | 2.9K | 2.55M | 68.29% | ↗ |
| 6 | 2024 | Pravin U. Dugel, M.D. Executive Chair, President and Chief Executive Officer | 464.5K | 886.1K | 8.29M | 8.87M | — | 57.8K | 18.57M | 92.42% | ↗ |
| 7 | 2024 | Antony Mattessich Former President and Chief Executive Officer | 245.6K | — | 934.5K | 2.00M | — | 5.60M | 8.78M | 33.47% | ↗ |
| 8 | 2024 | Peter Kaiser, M.D. Chief Development Officer | 365.1K | 242.0K | 3.88M | 2.12M | — | 29.8K | 6.63M | 90.39% | ↗ |
| 9 | 2024 | Jeffrey S. Heier, M.D. Chief Scientific Officer | 365.1K | 220.0K | 3.88M | 2.12M | — | 21.6K | 6.60M | 90.81% | ↗ |
| 10 | 2024 | Donald Notman Chief Operating Officer and Chief Financial Officer | 497.1K | 274.2K | 881.4K | 413.7K | — | 2.9K | 2.07M | 62.59% | ↗ |
| 11 | 2023 | Antony Mattessich Former President and Chief Executive Officer | 686.4K | 459.5K | 684.0K | 1.44M | — | 3.0K | 3.28M | 64.94% | ↗ |
| 12 | 2023 | Rabia Gurses Ozden, M.D. Chief Medical Officer | 462.8K | 221.8K | 215.6K | 577.2K | — | 2.8K | 1.48M | 53.56% | ↗ |
| 13 | 2023 | Donald Notman Chief Financial Officer | 464.6K | 212.2K | 215.6K | 448.2K | — | 3.0K | 1.34M | 49.40% | ↗ |
| 14 | 2023 | Donald Notman Chief Operating Officer and Chief Financial Officer | 464.6K | 212.2K | 215.6K | 448.2K | — | 3.0K | 1.34M | 49.40% | ↗ |
| 15 | 2022 | Antony Mattessich President and Chief Executive Officer | 660.0K | 386.1K | 984.2K | 2.07M | — | 3.3K | 4.10M | 74.41% | ↗ |
| 16 | 2022 | Antony Mattessich Former President and Chief Executive Officer | 660.0K | 386.1K | 984.2K | 2.07M | — | 3.3K | 4.10M | 74.41% | ↗ |
| 17 | 2022 | Donald Notman Chief Financial Officer | 446.7K | 180.9K | 292.8K | 615.0K | — | 3.3K | 1.54M | 59.00% | ↗ |
| 18 | 2022 | Rabia Gurses Ozden, M.D. Chief Medical Officer | 427.9K | 190.2K | 267.3K | 599.1K | — | 3.3K | 1.49M | 58.23% | ↗ |
| 19 | 2021 | Antony Mattessich President and Chief Executive Officer | 630.0K | 410.0K | — | 6.05M | — | 3.3K | 7.10M | 85.30% | ↗ |
| 20 | 2021 | Michael Goldstein, M.D. President, Ophthalmology and Chief Medical Officer | 488.3K | 244.2K | — | 3.33M | — | 3.3K | 4.06M | 81.89% | ↗ |
| 21 | 2021 | Patricia Kitchen Former Chief Operating Officer | 168.4K | — | — | 2.93M | — | 293.0K | 3.39M | 86.38% | ↗ |
| 22 | 2021 | Donald Notman Chief Financial Officer | 431.6K | 194.3K | — | 2.53M | — | 3.3K | 3.16M | 80.07% | ↗ |
| 23 | 2020 | Philip C. Strassburger, Esq. General Counsel | 125.6K | 157.0K | — | 2.13M | — | — | 2.41M | 88.29% | ↗ |
| 24 | 2020 | Antony Mattessich President and Chief Executive Officer | 600.0K | 432.0K | — | 1.13M | — | 750.00 | 2.16M | 52.26% | ↗ |
| 25 | 2020 | Michael Goldstein, M.D. President, Ophthalmology and Chief Medical Officer | 440.0K | 202.4K | — | 675.1K | — | 750.00 | 1.32M | 51.21% | ↗ |
| 26 | 2020 | Donald Notman Chief Financial Officer | 415.0K | 199.2K | — | 675.1K | — | 750.00 | 1.29M | 52.33% | ↗ |
| 27 | 2020 | Patricia Kitchen Former Chief Operating Officer | 398.8K | 199.2K | — | 675.1K | — | — | 1.27M | 53.03% | ↗ |
| 28 | 2019 | Amarpreet Sawhney, Ph.D. Former Chairman of the Board | 183.8K | — | — | 2.14M | — | 434.00 | 2.33M | 92.09% | ↗ |
| 29 | 2019 | Antony Mattessich President and Chief Executive Officer | 581.8K | 325.0K | — | 1.22M | — | 750.00 | 2.13M | 57.31% | ↗ |
| 30 | 2019 | Patricia Kitchen, Ph.D. Chief Operations Officer | 176.3K | 153.1K | — | 488.5K | — | 310.2K | 1.13M | 43.30% | ↗ |
| 31 | 2019 | Daniel Bollag, Ph.D. Former Chief Strategy Officer | 353.0K | — | — | 658.0K | — | 29.9K | 1.04M | 63.22% | ↗ |
| 32 | 2019 | Michael Goldstein, M.D. Chief Medical Officer | 423.9K | 126.1K | — | 457.0K | — | 750.00 | 1.01M | 45.35% | ↗ |
| 33 | 2019 | Michael Goldstein, M.D. President, Ophthalmology and Chief Medical Officer | 423.9K | 126.1K | — | 457.0K | — | 750.00 | 1.01M | 45.35% | ↗ |
| 34 | 2018 | Antony Mattessich President and Chief Executive Officer | 564.9K | 372.8K | — | 1.59M | — | 96.1K | 2.63M | 60.64% | ↗ |
| 35 | 2018 | Amarpreet Sawhney, Ph.D. Former Chairman of the Board | 288.8K | 158.8K | — | 575.2K | — | 724.00 | 1.02M | 56.19% | ↗ |
| 36 | 2018 | Amarpreet Sawhney, Ph.D. Chairman of the Board and former President and Chief Executive Officer | 288.8K | 158.8K | — | 575.2K | — | 724.00 | 1.02M | 56.19% | ↗ |
| 37 | 2018 | Kevin Hanley Senior Vice President, Technical Operations | 330.1K | 152.4K | — | 523.8K | — | 750.00 | 1.01M | 52.01% | ↗ |
| 38 | 2018 | Michael Goldstein, M.D. Chief Medical Officer | 403.7K | 127.2K | — | 369.4K | — | 750.00 | 901.1K | 41.00% | ↗ |
| 39 | 2018 | Daniel Bollag, Ph.D. Former Chief Strategy Officer | 339.2K | 130.6K | — | 226.1K | — | 750.00 | 696.6K | 32.45% | ↗ |
| 40 | 2017 | Antony Mattessich President and Chief Executive Officer | 237.6K | 596.5K | — | 5.19M | — | 155.0K | 6.18M | 84.00% | ↗ |
| 41 | 2017 | Amarpreet Sawhney, Ph.D. Executive Chairman of the Board and Former President and Chief Executive Officer | 440.9K | 121.3K | — | 1.24M | — | 741.00 | 1.80M | 68.73% | ↗ |
| 42 | 2017 | Amarpreet Sawhney, Ph.D. Chairman of the Board and former President and Chief Executive Officer | 440.9K | 121.3K | — | 1.24M | — | 741.00 | 1.80M | 68.73% | ↗ |
| 43 | 2017 | James Fortune Former Chief Operating Officer and Interim Chief Financial Officer | 433.1K | 62.1K | — | 473.8K | — | 750.00 | 969.7K | 48.86% | ↗ |
| 44 | 2017 | Michael Goldstein Chief Medical Officer | 107.7K | 37.2K | — | 685.2K | — | 219.00 | 830.4K | 82.52% | ↗ |
| 45 | 2017 | Donald Notman Chief Financial Officer | 102.3K | 40.4K | — | 634.5K | — | 219.00 | 777.4K | 81.62% | ↗ |
| 46 | 2016 | Amarpreet Sawhney, Ph.D. President and Chief Executive Officer | 540.8K | 237.9K | — | 968.4K | — | 158.00 | 1.75M | 55.42% | ↗ |
| 47 | 2016 | Amarpreet Sawhney, Ph.D. Executive Chairman of the Board and Former President and Chief Executive Officer | 540.8K | 237.9K | — | 968.4K | — | 158.00 | 1.75M | 55.42% | ↗ |
| 48 | 2016 | James Fortune Former Chief Operating Officer and Interim Chief Financial Officer | 401.9K | 128.6K | — | 330.9K | — | 188.00 | 861.6K | 38.40% | ↗ |
| 49 | 2016 | James Fortune Chief Operating Officer | 401.9K | 128.6K | — | 330.9K | — | 188.00 | 861.6K | 38.40% | ↗ |
| 50 | 2016 | W. Bradford Smith Former Chief Financial Officer | 345.2K | 113.9K | — | 289.5K | — | 188.00 | 748.8K | 38.66% | ↗ |
| 51 | 2015 | Amarpreet Sawhney, Ph.D. President and Chief Executive Officer | 522.5K | 201.2K | — | 3.27M | — | 1.3K | 4.00M | 81.86% | ↗ |
| 52 | 2015 | James Fortune Chief Operating Officer | 388.3K | 110.7K | — | 1.52M | — | 2.8K | 2.02M | 75.19% | ↗ |
| 53 | 2015 | W. Bradford Smith Former Chief Financial Officer | 333.5K | 95.1K | — | 1.06M | — | 3.7K | 1.49M | 71.01% | ↗ |
| 54 | 2015 | W. Bradford Smith Chief Financial Officer | 333.5K | 95.1K | — | 1.06M | — | 3.7K | 1.49M | 71.01% | ↗ |
| 55 | 2014 | Amarpreet Sawhney, Ph.D. President and Chief Executive Officer | 500.0K | 288.8K | — | 696.8K | — | 135.00 | 2.39M | 29.20% | ↗ |
| 56 | 2014 | W. Bradford Smith Chief Financial Officer | 248.8K | 76.8K | — | 732.6K | — | 1.2K | 1.06M | 69.16% | ↗ |
| 57 | 2014 | Bradford Smith Chief Financial Officer | 248.8K | 76.8K | — | 732.6K | — | 1.2K | 1.06M | 69.16% | ↗ |
| 58 | 2014 | James Fortune Chief Operating Officer | 375.2K | 135.1K | — | 439.0K | — | 1.9K | 951.2K | 46.15% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pravin U. Dugel | Executive Chairman, President & Chief Executive Officer | 1M | — |
| Peter K. Kaiser | Chief Development Officer | 698.9K | — |
| Donald Notman Jr. | CFO, COO & Principal Accounting Officer (Leave of Absence) | 679.8K | male |
| Jeffrey S. Heier | Chief Scientific Officer | 676.6K | — |
| Todd Anderman | Chief Legal Officer & Corporate Secretary | — | male |
| William H. Ransone | Vice President of Global Sales & Marketing | — | male |
| Barry Rubenstein | Chief Human Resources Officer | — | male |
| William S. Slattery Jr. | Vice President of Investor Relations | — | male |
| Jason Robins | Senior VP of Finance, Interim CFO & Principal Accounting Officer | — | male |
| Peter K. Jarrett | Chief Technical Officer | — | — |
| Steve Meyers | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OCUL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
